XSWX
LONN
Market cap46bUSD
Sep 17, Last price
545.00CHF
1D
1.23%
1Q
9.28%
Jan 2017
233.73%
IPO
427.69%
Name
Lonza Group AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Related entities
Subsidiaries (14)
CAPSUGEL BELGIUM
CAPSUGEL FRANCE
LONZA FINANCE INTERNATIONAL NV
LONZA INDIA PRIVATE LIMITED
LONZA SALES AG
LONZA SWISS FINANZ AG
LONZA VERVIERS
CAPSUGEL HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
CAPSUGEL ITALY SOCIETÀ A RESPONSABILITÀ LIMITATA
CAPSUGEL SPAIN SL
INNOVATIVE WATER CARE EUROPE SAS
INNOVATIVE WATER CARE LIMITED
LONZA BIOLOGICS PLC
MW ENCAP LIMITED
Key people
Independent member of Board · since 2013
Jean-Daniel Gerber
Independent member of Board · since 2011
Angelica Kohlmann
Independent Member of the Board · since 2018
Lead Independent Member of the Board · since 2019
Antonio Trius
Independent Member of Board · since 2013
Olivier Verscheure
Independent Member of the Board · since 2018
Legal address
MUNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
BASEL, BS 4052
CH
Headquarters
MÜNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
BASEL, BS 4052
CH
Previous name
AXERA AG
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||